|
|
US 7,341,993 B2 |
|
| Cross-linked glycopeptide—cephalosporin antibiotics |
| Paul R. Fatheree, San Francisco, Calif. (US); Martin S. Linsell, San Francisco, Calif. (US); Daniel D. Long, San Francisco, Calif. (US); Daniel Marquess, Half Moon Bay, Calif. (US); Edmund J. Moran, San Francisco, Calif. (US); Matthew B. Nodwell, San Francisco, Calif. (US); S. Derek Turner, Pacifica, Calif. (US); and James Aggen, Burlingame, Calif. (US) |
| Assigned to Theravance, Inc., South San Francisco, Calif. (US) |
| Filed on Jun. 30, 2005, as Appl. No. 11/172,303. |
| Application 11/172303 is a continuation of application No. 10/269471, filed on Oct. 11, 2002, granted, now 6,974,797. |
| Claims priority of provisional application 60/328889, filed on Oct. 12, 2001. |
| Prior Publication US 2005/0239691 A1, Oct. 27, 2005 |
| Int. Cl. A61K 38/16 (2006.01); A61K 38/00 (2006.01)
|
